Global Demand for Precision Orthopedic Devices Surges as the Drill Surgical Power Tool Market, Valued at USD 2.3 Billion in 2024, is Set to Reach USD 4.5 Billion by 2033, advancing at a Robust CAGR of ...

HERPEN, Netherlands, Oct. 9, 2025 /PRNewswire/ -- Orexa B.V., a Dutch life sciences company focused on improving recovery and nutritional status in patients, today announced positive interim results ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab lowered risk for major adverse CV events in a primary prevention population. Evolocumab is the first ...

When added to statins or other cholesterol-lowering agents, the PCSK9 inhibitor evolocumab (Repatha) reduces the risk of MACE better than standard therapy alone in individuals with no prior history of ...

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...

The US Food and Drug Administration has expanded the indication for evolocumab (Repatha) to include a wider swath of patients at high risk for cardiovascular disease due to elevated LDL cholesterol ...

In this episode of The DrBicuspid.com Podcast, Editor-in-Chief Kevin Henry speaks with Michelle Lee, the executive director of the Association for Dental Safety (ADS), about the significant changes in ...

THURSDAY, July 10, 2025 (HealthDay News) -- Almost 15 percent of U.S. adults aged 50 to 80 years are taking aspirin for primary cardiovascular disease prevention, according to a brief report published ...

Please provide your email address to receive an email when new articles are posted on . Up to 15% of older adults may routinely use aspirin for primary prevention. Many continue use despite knowing ...

People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of preventive management than in the general population. Last year, an HHS panel ...